## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number 3235-0287 Estimated average burden hours per response: 0.5

### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4

or Section su(n) of the investment Company Act of 1940										
1. Name and Address of Repor	•		2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ ISIS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
CROOKE STANLE	<u>1 1</u>			Х	Director	10% Owner				
	(m)			х	Officer (give title below)	Other (specify below)				
(Last) (First) (Middle) C/O ISIS PHARMACEUTICALS, INC.		(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	Chairman, President and CEO						
C/O ISIS PHARMACEU	IICALS, INC.		01/02/2014							
2855 GAZELLE COURT										
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individua	l or Joint/Group Filing (Check Applicable Li	ine)				
CARLSBAD	CA	92010	······································	Х	Form filed by One Reporting Person					
	GA	52010			Form filed by More than One Reporting I	Person				
(City)	(State)	(Zip)								
(0.9)	(olulo)	(=:+)								
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr.
	(wonth/bay/rear)	(Month/Day/Year)	Code V		Amount	(A) or (D)	Price	(Instr. 3 and 4)	(insu. 4)	4)
Common Stock	01/02/2014	01/02/2014	<b>M</b> <sup>(1)</sup>		25,000 <sup>(1)</sup>	Α	\$14.47	26,661	D	
Common Stock	01/02/2014	01/02/2014	<b>S</b> <sup>(1)</sup>		25,000 <sup>(1)</sup>	D	\$39.253	1,661	D	
Common Stock	01/02/2014	01/02/2014	<b>M</b> <sup>(1)</sup>		4,000(1)	Α	\$14.47	5,661	D	
Common Stock	01/02/2014	01/02/2014	<b>S</b> <sup>(1)</sup>		4,000(1)	D	\$40	1,661	D	
Common Stock	01/02/2014	01/02/2014	<b>M</b> <sup>(2)</sup>		2,500 <sup>(2)</sup>	Α	\$14.47	2,674	I	By Wife
Common Stock	01/02/2014	01/02/2014	<b>S</b> <sup>(2)</sup>		2,500 <sup>(2)</sup>	D	\$39.253	174	I	By Wife
Common Stock								725,391	I	By Trust

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	n Date, (Instr. 8)		Securities Acquired (A) or		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	,			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Employee Stock Option (right to buy)	\$39.87	01/02/2014	01/02/2014	Α		187,500		01/02/2015 <sup>(3)</sup>	01/01/2021	Common Stock	187,500	\$0	187,500	D	
Employee Stock Option (right to buy)	\$39.87	01/02/2014	01/02/2014	A		8,500		01/02/2015 <sup>(4)</sup>	01/01/2021	Common Stock	8,500	\$0	8,500	I	By Wife

### Explanation of Responses:

1. Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 8/6/13.

A cquired as a result of exercising a stock option pursuant to a Rule 1005-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 1005-1 Trading Plan adopted by the reporting person is wife on 8/6/13. 3. Grant of 1/2/14 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/15. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 46,875 shares per year. The option shall be fully vested and exercisable on 1/2/18. The option is exercisable as to 0 shares on 1/2/14.

4. Grant of 1/2/14 to reporting person's wife of stock options under the Isis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/15. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 2,125 shares per year. The option shall be fully vested and exercisable on 1/2/18. The option is exercisable as to 0 shares on 1/2/14.

#### Remarks:

/s/Stanley T. Crooke \*\* Signature of Reporting Person 01/02/2014 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number

Know all by these presents, that the undersigned hereby constitutes and appoints each of Stanley T. Crooke and B. Lynne Parshall, signing individually, the undersigned (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of Isis Pharmaceuticals, Inc. (1) (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best in The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, ( This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with 1

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 9th day of September, 2002.

/s/Stanley T. Crooke